A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. (Q51763771)
Jump to navigation
Jump to search
scientific article published on 18 March 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. |
scientific article published on 18 March 2009 |
Statements
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. (English)
1 reference
Olivier Rixe
1 reference
Hope S Rugo
1 reference
Denise A Yardley
1 reference
Sandra X Franco
1 reference
Stephen R Johnston
1 reference
Miguel Martin
1 reference
Banu K Arun
1 reference
Stephen P Letrent
1 reference
18 March 2009
1 reference
64
1 reference
6
1 reference
1139-1148
1 reference